Products
Fletikumab Biosimilar Monoclonal Antibody (IL-20) for Research
Pre-Made Fletikumab biosimilar, Whole mAb, Anti-IL20 Antibody: Anti-IL-20/IL10D/ZCYTO10 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Fletikumab (NNC0109-0012) (INN) is a monoclonal antibody designed for the treatment of rheumatoid arthritis.
Order Information
| Catalog No. | Package | List Price(In USD) | Discount off | Discount Price |
|---|---|---|---|---|
| GMP-Bios-ab-217-1mg | 1mg | 3090 |
Size： 1mg | 10mg | 100mg
Product Details
| Products Name (INN Index) | Pre-Made Fletikumab biosimilar, Whole mAb, Anti-IL20 Antibody: Anti-IL-20/IL10D/ZCYTO10 therapeutic antibody |
| INN Name | Fletikumab |
| Target | IL20 |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1 Isotype | IgG4 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Discontinued |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2013 |
| Year Recommended | 2014 |
| Companies | ZymoGenetics;Novo Nordisk |
| Conditions Approved | na |
| Conditions Active | na |
| Conditions Discontinued | Psoriasis;Rheumatoid arthritis |
| Development Tech | na |
About target - IL20
1. Protein Interleukin-20
2. Gene IL20
3. Organism Homo sapiens (Human)
Function
Proinflammatory and angiogenic cytokine that may be involved in epidermal function and psoriasis. Angiogenic and proliferative activities are antagonized by IL10. May act through STAT3.
